echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Is the market value of the vaccine leader nearly 100 billion yuan in danger?

    Is the market value of the vaccine leader nearly 100 billion yuan in danger?

    • Last Update: 2020-04-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Article Liang Jian Zhifei biology, a leading domestic vaccine enterprise, issued a notice that the AC group meningococcal (combined) type B Haemophilus influenzae (combined) combined vaccine (hereinafter referred to as "AC Hib vaccine") produced by its wholly-owned subsidiary Beijing Zhifei green bamboo biopharmaceutical Co., Ltd

    (hereinafter referred to as "Zhifei green bamboo") received the approval opinion from Beijing Drug Administration on February 19, 2020: no further injection Volume

    The "AC Hib vaccine" independently developed and produced by Zhifei green bamboo is used to prevent group A and group C Neisseria meningitidis and infectious diseases such as meningitis, pneumonia, septicemia, cellulitis, arthritis and epiglottis caused by Haemophilus influenzae type B

    On April 2, 2014, AC Hib vaccine obtained the drug registration approval from the former State Food and Drug Administration (approval No.: 2014s00240), approved the product registration, and issued the drug approval number (gyzz s20140003), which is valid for 5 years

    On November 8, 2018, Zhifei green bamboo submitted the application for re registration of AC Hib vaccine to Beijing food and drug administration

    After 16 months of waiting, the application for re registration failed

    Beijing Drug Administration gave reasons for not re registration: the information provided by the applicant has not met the requirements of the approval conclusion of the original drug registration documents

    For the impact of this re registration failure, Zhifei biology said that the sales revenue of AC Hib vaccine in 2019 accounted for about 10% of the company's main business revenue, and the product did not obtain the re registration approval, which is expected to have a certain impact on the company's performance in 2020

    It can be seen that the lack of approval of this AC Hib vaccine will greatly affect the performance of Zhifei biology in 2020

    Of course, the power of this effect depends on the future R & D adjustment direction of Zhifei biology

    However, it also shows the disadvantages of Zhifei biology in R & D and sales, that is, too much dependence on a single variety is very likely to lead to unstable performance of the company, even if this is the case The next affected company is Zhifei biological's subsidiary

    Although its exclusive AC Hib vaccine has not been approved for re registration, Zhifei biology also said in the announcement that the company is stepping up the development of AC Hib vaccine freeze-dried dosage form and will timely fulfill the obligation of information disclosure according to the follow-up progress

    The implication of Zhifei biology is that in 2020, the company will focus on the research and development of AC Hib vaccine lyophilized dosage form

    In addition, Zhifei biology will mainly promote the upgraded AC combined vaccine and Hib vaccine products in 2020, which is also expected to promote the company's own varieties to achieve a steady growth of 20%

    Why is it not approved normally for two consecutive years? In fact, it is not the first time that the AC Hib vaccine has not been approved

    Almost in the same period last year, on April 1, 2019, Zhifei biology released a notice saying that its exclusive varieties have not received the re registration approval, which means that the production of AC Hib vaccine, which accounts for a large proportion of its profits, will be suspended

    As a result, the stock price of Zhifei biology will be suspended the next day

    What is the reason why the same product has not been approved for two consecutive years? According to the statement of Zhifei biology last year, the suspension of AC Hib vaccine is not due to quality problems, because in October 2018, before applying for registration, Zhifei biology was affected by the forgery of Changsheng biology, the exposure of bribery scandal and the urgent departure of the two shareholders, which caused Zhifei biology to stop under multiple profits

    More than that, it may be the impact of vaccine forgery, regulatory epidemic Miao registration may be tightened

    Last year's failure to get approval was due to the industry's increased supervision caused by Changchun Changsheng vaccine fraud, but this year's failure to get approval again

    Zhifei biology has not explained the reasons in the announcement

    Zhifei biology said that the sales revenue of AC Hib vaccine in 2019 accounted for about 10% of the company's main business revenue, and the product has not obtained the re registration approval, which is expected to produce the company's 2020 performance Make a certain impact

    The risk cannot be underestimated

    In fact, AC Hib vaccine is a project launched by Zhifei biology in 2011

    Zhifei green bamboo, a wholly-owned subsidiary, is responsible for the implementation of AC Hib vaccine, with an investment of 307 million yuan

    Zhifei green bamboo is a subsidiary of Zhifei biology, which is mainly engaged in the R & D, production and sales of bacterial vaccine products mainly for the prevention of meningitis and pneumonia

    At present, its main performance growth point is the AC Hib triple vaccine

    According to the financial report of Zhifei biology, in 2016, Zhifei biology achieved a revenue of 450 million yuan and a net profit of 32.52 million yuan; Zhifei green bamboo achieved a revenue of 300 million yuan and a net profit of 93.187 million yuan; the annual batch issuance of AC Hib vaccines was 222000

    In 2017, Zhifei's biological revenue was 1.34 billion, with a net profit of 430 million; Zhifei's green bamboo revenue was 990 million, with a net profit of 430 million; the annual batch issuance of AC Hib vaccines was 4.704 million

    In 2018, Zhifei biological revenue was 5.23 billion yuan, with a net profit of 1.45 billion yuan; Zhifei green bamboo revenue was 1.24 billion yuan, with a net profit of 530 million yuan; the annual batch issuance of AC Hib vaccine was 6.437 million pieces

    According to the 2019 performance forecast released by Zhifei biology a few days ago, in 2019, the annual performance is expected to achieve a net profit of 2.250-2.540 billion

    Based on this figure, the profit of Zhifei biology AC Hib vaccine last year will be 225-254 million

    In addition to the cooperation with MSD, the cooperation with MSD will be a bright spot in the future performance development of Zhifei biology

    In fact, in China, the cooperation between Zhifei biology and MSD has been for 7 years

    The strong sales and promotion ability of Zhifei biological vaccine is the advantage of mosadong

    According to the 2019 half year report of Zhifei biology, its marketing network can cover 31 provinces, autonomous regions and municipalities directly under the central government, including more than 300 cities, more than 2600 districts and counties, and more than 30000 grassroots health service points (township vaccination points, community clinics)

    At present, there are 1792 sales personnel in Zhifei biology

    In 2017 and 2018, Zhifei biology won the exclusive right to act on the 4 and 9 Price HPV vaccine of MSD

    In the past years, the growth rate of lukewarm performance ushered in qualitative change

    In 2018, the net profit reached 1.451 billion, surpassing the biopharmaceutical leader Changchun hi tech

    In the first three quarters of 2019, Zhifei biology achieved a business income of 7.666 billion yuan, a year-on-year increase of 119.35%, and a net profit attributable to its parent of 1.763 billion yuan, a year-on-year increase of 62.25%

    In 2019, Zhifei's annual performance is expected to achieve a net profit of 2.250-2.540 billion

    Zhifei has also said that at present, the four price HPV has won the bid in 29 provincial-level units nationwide, and the promotion and sales work are also actively carried out

    Since the signing of the supplementary agreement on May 1, 2018, the nine price HPV vaccine has won the bid in five provincial units, and the bidding, promotion and sales of the above products have been actively promoted as planned

    It can be seen that although the situation of approval of self-developed products is not clear, the support of MSD has given a boost to the performance of Zhifei biology last year

    However, as the cooperation agreement with MSD is about to expire, what Zhifei biology needs to consider at present is the R & D process of its own products

    According to the 2019 half year report, at present, there are 22 products under research and 17 products are in the clinical stage

    The rich R & D pipeline is also the capital and foundation for Zhifei to get rid of MSD

    After all, even if it acts as an agent for more products of others, when the other party finds a more suitable partner, it also has the spare power to support the next development

    37
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.